Cardiovascular System – Cannabis and Cannabinoid Research

Cardiovascular System and ECS-Based Interactions

Clinical Considerations: 

The endocannabinoid system (ECS) is now recognized as an integral modulator of cardiovascular physiology. Its components—CB1 and CB2 receptors, endogenous ligands such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their synthesizing/degrading enzymes (e.g., FAAH, MAGL)—are found throughout cardiovascular tissues, including the heart, vascular endothelium, smooth muscle cells, and immune cells circulating in the bloodstream.

• 
  

  CB1 receptors are prominently expressed in vascular endothelial cells, cardiomyocytes, and sympathetic nerve terminals. Their activation can influence heart rate, vascular resistance, and blood pressure—often leading to transient vasodilation and hypotension.

  
  


• 
  

  CB2 receptors, though more sparsely distributed in cardiovascular tissues, are upregulated during inflammatory or ischemic stress. Their activation exerts anti-inflammatory, anti-fibrotic, and cytoprotective effects, particularly in atherosclerosis, myocardial infarction, and heart failure models.

  
  


• 
  

  Endocannabinoids (AEA, 2-AG) are synthesized on demand in response to stressors like ischemia, oxidative stress, and inflammation. They act locally to modulate vascular tone, limit immune overactivation, and reduce cardiomyocyte damage.

  
  


• 
  

  Non-classical targets such as TRPV1, PPAR-α/γ, and GPR55 (a putative cannabinoid receptor) also mediate endocannabinoid effects on vasodilation, lipid metabolism, and inflammatory signaling.

  
  

Collectively, these findings suggest that ECS signaling plays a nuanced, bidirectional role in cardiovascular health—supporting homeostasis under normal conditions, but becoming either protective or maladaptive depending on context, dose, and receptor balance.

Suboptimal ECS Signaling in Cardiovascular Disorders: A Brief Overview

Suboptimal endocannabinoid signalling—whether due to altered endocannabinoid levels, receptor overactivation or deficiency, or impaired enzymatic degradation—have been implicated in the pathogenesis of numerous cardiovascular diseases such as for example:

• Hypertension: Overactivation of CB1 receptors in vascular tissue may contribute to hypotensive or dysregulated vasomotor tone. Conversely, impaired CB2 signaling limits anti-inflammatory protection in vascular endothelium, promoting vascular stiffness and elevated blood pressure.


• Atherosclerosis: Suboptimal CB2 receptor activity reduces the ECS’s ability to counteract vascular inflammation, oxidative stress, and immune cell adhesion—all key drivers of atherosclerotic plaque development and progression.


• Myocardial Infarction (MI) and Ischemia-Reperfusion Injury: Low levels of cardioprotective endocannabinoids like 2-AG are associated with increased susceptibility to tissue damage following cardiac ischemia. Inadequate ECS modulation can amplify infarct size, inflammatory response, and arrhythmia risk.


• Heart Failure: Chronic ECS dysregulation—particularly CB1 overactivation in cardiomyocytes—has been associated with negative inotropic (strength of muscle contractions) effects and pathological remodeling. CB2 underactivity contributes to unresolved inflammation and fibrosis.


• Endothelial Dysfunction and Microvascular Disease: Impaired ECS tone disrupts endothelial nitric oxide signaling, increases vascular permeability, and promotes microcirculatory inflammation—factors that underpin diseases such as diabetic cardiomyopathy and peripheral artery disease.

Clinical Implications: 

Modulating components of the ECS through cannabinoid-based therapeutics has shown promising, though mixed, results in the treatment and prevention of cardiovascular conditions.

• Isolated Cannabinoids and Cardioprotection: Preclinical studies suggest that low-dose THC may exert cardioprotective effects by reducing oxidative stress, limiting infarct size during ischemia-reperfusion injury, and attenuating inflammatory responses via CB2 receptor activation. Similarly, CBD modulates cardiovascular function through 5-HT1A, TRPV1, and PPARγ, potentially reducing arrhythmias, vascular inflammation, and myocardial fibrosis in several animal models. In addition, by improving mood and reducing stress and anxiety—factors closely tied to cardiovascular risk—CBD may support heart health through both physiological and psychobehavioral pathways.


• CB2 Activation and Vascular Inflammation: CB2-selective agonists have demonstrated anti-atherogenic effects by suppressing immune cell migration, reducing endothelial dysfunction, and inhibiting plaque formation in models of atherosclerosis. These findings suggest therapeutic potential for ECS modulation in the early and progressive stages of vascular disease.


• Microvascular and Endothelial Function: Cannabinoid-based therapies—especially those targeting TRPV1, GPR55, and PPAR pathways—have shown efficacy in improving endothelial nitric oxide (NO) signaling, a key regulator of vascular tone and microcirculatory health. This is particularly relevant in diabetic vasculopathies and hypertensive heart disease.

A Note on Whole-Plant Cannabis and Mixed Findings

While isolated cannabinoids such as THC, CBD, and CB2 agonists show therapeutic promise, clinical studies on whole-plant cannabis have yielded mixed or inconclusive results, largely due to:

• 
  

  Lack of chemotype specification (e.g., THC:CBD ratios, terpene profile)

  
  


• 
  

  Variable dosing regimens

  
  


• 
  

  Diverse routes of administration and patient populations

  
  

Importantly, higher doses of THC—especially in THC-dominant chemovars—have been associated with increased heart rate, anxiety, and sympathetic activation, which may exacerbate cardiac ischemia or arrhythmia risk in vulnerable individuals (e.g., those with pre-existing heart disease or heightened stress response).

In contrast, balanced or CBD-rich formulations may offer anxiolytic and anti-inflammatory benefits without these adverse cardiovascular effects, especially when personalized and titrated appropriately.

Clinical Takeaway:

By targeting dysregulation within the endocannabinoid system, cannabinoid-based interventions may offer meaningful therapeutic support in cardiovascular care. Preclinical and early clinical data suggest that modulating CB1, CB2, TRPV1, GPR55, PPARγ, and 5-HT1A signaling can help:

• 
  

  Reduce vascular inflammation and atherogenesis

  
  


• 
  

  Improve endothelial function and nitric oxide bioavailability

  
  


• 
  

  Stabilize heart rhythm and reduce arrhythmias

  
  


• 
  

  Protect myocardial tissue during ischemic events

  
  


• 
  

  Lower oxidative stress and sympathetic overactivation

  
  

In particular, low-dose THC and CBD-rich formulations have shown potential for cardioprotection—especially when tailored to the individual’s condition, dosage needs, and emotional state. However, higher THC doses may trigger anxiety and sympathetic activation, increasing cardiovascular risk in vulnerable populations.

This underscores the importance of chemotype selection, dose titration, and clinical monitoring in cardiovascular applications. While more rigorous human trials are needed, ECS modulation represents a promising adjunct or preventive strategy—especially for conditions marked by inflammation, vascular dysfunction, or stress-related cardiac events.